Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “AstraZeneca”

Safety of Oral Resin for Treatment of Hyperkalemia in Chinese Patients With Renal InsufficiencyCompleted
NCT05462119N/AUpdated Dec 3, 2024
Sponsor: AstraZeneca
Hyperkalaemia
China
A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast CancerCompleted
NCT02216786Phase 2Updated Dec 2, 2024
Sponsor: Queen Mary University of London
Estrogen Receptor Positive Breast Cancer
France, Georgia, Germany, Hungary, Portugal +4 more
A Study to Investigate the Use of Benralizumab in Patients With Bullous Pemphigoid.Terminated
NCT04612790Phase 3Updated Nov 29, 2024
Sponsor: AstraZeneca
Bullous Pemphigoid
United States, Australia, Bulgaria, China, France +6 more
A Multicountry, Multicentre, Non-interventional, Retrospective Study to Determine Real-world Treatment Patterns and Associated Outcomes After First Line Osimertinib in Patients With Advanced and Metastatic NSCLC EGFRm in the GCC RegionCompleted
NCT06039683N/AUpdated Nov 29, 2024
Sponsor: AstraZeneca
Carcinoma, Non-Small-Cell Lung
Kuwait, Qatar, Saudi Arabia, United Arab Emirates
Durvalumab Plus Chemotherapy in ES-SCLC (Oriental)Completed
NCT04449861Phase 3Updated Nov 27, 2024
Sponsor: AstraZeneca
Small Cell Lung Carcinoma Extensive Disease
China
Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the BladderTerminated
NCT02891161Phase 1, Phase 2Updated Nov 27, 2024
Sponsor: Monika Joshi, MD
Urothelial Cancer
United States
Study to Evaluate Pharmacokinetic Comparability Between AZD7442 Co-formulation (AZD8895 + AZD1061) vs AZD8895 and AZD1061 Individually in Adult Healthy ParticipantsCompleted
NCT05166421Phase 1Updated Nov 25, 2024
Sponsor: AstraZeneca
Corona Virus Disease
United States
Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell LymphomaCompleted
NCT04930536Phase 4Updated Nov 22, 2024
Sponsor: AstraZeneca
Chronic Lymphocytic Leukemia and Relapsed and Refractory Mantle Cell Lymphoma
India
Benralizumab Pregnancy Exposure StudyTerminated
NCT03794999N/AUpdated Nov 22, 2024
Sponsor: AstraZeneca
Asthma
United States
Effectiveness of the Oxford-AstraZeneca COVID-19 Vaccine as a 2nd Booster, the REFORCO-Brazil StudyCompleted
NCT05697705N/AUpdated Nov 21, 2024
Sponsor: AstraZeneca
COVID-19
Brazil
Study of T-DXd Monotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma Who Have Received 2 or More Prior RegimensCompleted
NCT04989816Phase 2Updated Nov 21, 2024
Sponsor: AstraZeneca
Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
China
A Study to Assess the PK, PD, Safety and Tolerability of Eplontersen in Healthy Chinese VolunteersCompleted
NCT06527755Phase 1Updated Nov 21, 2024
Sponsor: AstraZeneca
Transthyretin-mediated Amyloidosis
China
A Study to Evaluate the Safety and Tolerability of AZD7442 in Chinese AdultsCompleted
NCT05184062Phase 2Updated Nov 21, 2024
Sponsor: AstraZeneca
Coronavirus Disease 2019 (COVID-19)
China
Efficacy, Safety and Tolerability of AZD9977 and Dapagliflozin in Participants With Heart Failure and Chronic Kidney DiseaseCompleted
NCT04595370Phase 2Updated Nov 19, 2024
Sponsor: AstraZeneca
Heart Failure · Chronic Kidney Disease
United States, Belgium, Bulgaria, Canada, Czechia +17 more
Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 MutationCompleted
NCT02953457Phase 2Updated Nov 19, 2024
Sponsor: Roswell Park Cancer Institute
BRCA1 Gene Mutation · BRCA2 Gene Mutation · Ovarian Serous Adenocarcinoma · Recurrent Fallopian Tube Carcinoma
United States
REVITALIZE: A Telehealth Intervention for Women With Advanced Ovarian Cancer and PARP Inhibitor-Related FatigueCompleted
NCT04525183NAUpdated Nov 15, 2024
Sponsor: Dana-Farber Cancer Institute
Ovarian Cancer · Fatigue · Coping Behavior · Coping Skills
United States
A Study to Assess the Effect of AZD4041 on Respiratory Drive in Recreational Opioid Users.Completed
NCT05587998Phase 1Updated Nov 15, 2024
Sponsor: AstraZeneca
Opioid Use Disorder
United States
Saracatinib in the Treatment of Idiopathic Pulmonary FibrosisActive Not Recruiting
NCT04598919Phase 1, Phase 2Updated Nov 14, 2024
Sponsor: National Jewish Health
Idiopathic Pulmonary Fibrosis (IPF)
United States
To Assess Safety of Fixed Dose Combination of Dapagliflozin and Saxagliptin in Type 2 Diabetes Mellitus PatientsCompleted
NCT04445714Phase 4Updated Nov 12, 2024
Sponsor: AstraZeneca
Type 2 Diabetes Mellitus
India
18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent GlioblastomaCompleted
NCT03732352Phase 2Updated Nov 12, 2024
Sponsor: Jonsson Comprehensive Cancer Center
EGFR Gene Amplification · EGFR Gene Mutation · Glioblastoma · Recurrent Glioblastoma
United States
Developing ctDNA Guided Adjuvant Therapy for Gastrooesophageal CancerRecruiting
NCT05965479Phase 2Updated Nov 12, 2024
Sponsor: University of Southampton
Gastrooesophageal Cancer
United Kingdom
Dapagliflozin on Volume Vascular Outcomes.Completed
NCT04869124Phase 4Updated Nov 12, 2024
Sponsor: Frank Ruschitzka
Heart Failure，Congestive
Switzerland
Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of BalcinrenoneCompleted
NCT06388616Phase 1Updated Nov 12, 2024
Sponsor: AstraZeneca
Hepatic Impairment
United States
Study to Evaluate the Effects of MEDI6012 on Apolipoprotein B100 MetabolismTerminated
NCT03773172Phase 2Updated Nov 12, 2024
Sponsor: Columbia University
Cardiovascular Diseases
United States
Neoadjuvant Tremelimumab and Durvalumab With Gem/Cis in Intrahepatic CholangiocarcinomaWithdrawn
NCT06017297Phase 2Updated Nov 12, 2024
Sponsor: Georgetown University
Borderline Resectable Carcinoma · Biliary Tract Cancer

Previous page Next page